Måseide RJ, Berntorp E, Astermark J, Olsson A, Bruzelius M, Frisk T, Nummi V, Lassila R, Strandberg K, Tjønnfjord GE, Holme PA (2024)
Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study)
Res Pract Thromb Haemost, 8 (8), 102611
DOI 10.1016/j.rpth.2024.102611, PubMed 39807249

Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, Shah A, Holme PA, Poulsen LH, Meijer K, Simpson M, Mancuso ME (2024)
Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Drugs R D (in press)
DOI 10.1007/s40268-024-00494-2, PubMed 39702563

Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme PA, Álvarez-Román MT, Biron-Andréani C, Malmström H, Bystrická L, Lethagen S, A‐SURE Study Group (2024)
Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study
Eur J Haematol, 114 (2), 248-257
DOI 10.1111/ejh.14309, PubMed 39434416